Vanda Pharmaceuticals (VNDA) sNDA for Fanapt Approved by U.S. FDA for Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/28/2022
- Wall Street rallies, snaps longest weekly losing streak in decades
- 'Always Bet on Michael': Dell (DELL) Stock Soars After Crushing Estimates, Analysts Say Results are Impressive
- Credit Suisse Says Tesla (TSLA) Stock Offers an Attractive Entry Point, Sees Nearly 60% Upside From Here
- Citi Downgrades US Equities to Neutral on Recession Risk
- Elon Musk Says Recession Could Last 12 to 18 Months, But 'Actually a Good Thing'
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Summer Rally Bandwagon is Growing, Most Investors Expecting Bear Market Rally to Play the 'Jackson Hole Pivot' - Bank of America
- Kohl's (KSS) Ticks Lower as Another Bidder Losing Interest
- Caterpillar (CAT) Becomes Sponsor of Major League Soccer
- White House says no decision made on student loan forgiveness
- Pre-Open Stock Movers 05/27: Dell, Ulta Surge on Earnings Beats; Gap Plunges (more...)
- After-Hours Stock Movers 05/26: Ulta, Dell Jump on Earnings; Gap, American Eagle Sink (more...)
- Pre-Open Stock Movers 05/26: Retailers Dollar Tree, Macy's, and Williams-Sonoma Jump on Results; Nutanix, Snowflake, NVIDIA Fall (more...)
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
May 26, 2016 4:30 PM EDTWASHINGTON, May 26, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to describe the effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) placebo-controlled clinical study which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The study data submitted in the sNDA came from... More
